Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
37.42
59.36
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Ultragenyx Pharmaceutical Inc
Wall Street
Price Targets
RARE Price Targets Summary
Ultragenyx Pharmaceutical Inc
According to Wall Street analysts, the average 1-year price target for
RARE
is 94.42 USD
with a low forecast of 48.48 USD and a high forecast of 147 USD.
RARE Last Price Targets
Ultragenyx Pharmaceutical Inc
The latest public price target was made on Nov 6, 2024 by
Ed Arce
from
H.C. Wainwright
,
who expects
RARE
stock to
rise by 102%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Ed Arce
H.C. Wainwright
|
95
USD
Upside 102% |
2 weeks ago
Nov 6, 2024
|
Ultragenyx Pharma (RARE) PT Raised to $95 at H.C. Wainwright
StreetInsider
|
|
Joseph Schwartz
Leerink Partners
|
85
USD
Upside 80% |
2 weeks ago
Nov 6, 2024
|
Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE)
StreetInsider
|
Salveen Richter
Goldman Sachs
|
67
USD
Upside 42% |
5 months ago
Jun 6, 2024
|
Goldman Sachs Upgrades Ultragenyx Pharma (RARE) to Buy
StreetInsider
|
Dae Gon Ha
Stifel Nicolaus
|
127
USD
Upside 169% |
5 months ago
May 31, 2024
|
Ultragenyx Pharma (RARE) PT Raised to $127 at Stifel
StreetInsider
|
Christopher Raymond
Raymond James
|
135
USD
Upside 186% |
5 months ago
May 31, 2024
|
Piper Sandler Reiterates Overweight Rating on Ultragenyx Pharma (RARE)
StreetInsider
|
Joel Beatty
Robert W. Baird
|
72
USD
Upside 53% |
5 months ago
May 31, 2024
|
Ultragenyx Pharma (RARE) PT Raised to $72 at Baird
StreetInsider
|
Whitney Ijem
Canaccord Genuity
|
111
USD
Upside 136% |
5 months ago
May 31, 2024
|
Ultragenyx Pharma (RARE) PT Raised to $111 at Canaccord Genuity
StreetInsider
|
|
Dae Gon Ha
Stifel Nicolaus
|
124
USD
Upside 163% |
7 months ago
Apr 15, 2024
|
Stifel Reiterates Buy Rating on Ultragenyx Pharma (RARE)
StreetInsider
|
|
Christopher Raymond
Raymond James
|
130
USD
Upside 176% |
7 months ago
Apr 15, 2024
|
Piper Sandler Reiterates Overweight Rating on Ultragenyx Pharma (RARE)
StreetInsider
|
Unknown Analyst
Morgan Stanley
|
95
USD
Upside 102% |
1 year ago
Feb 3, 2023
|
Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $95
Benzinga
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is RARE's stock price target?
Price Target
94.42
USD
According to Wall Street analysts, the average 1-year price target for
RARE
is 94.42 USD
with a low forecast of 48.48 USD and a high forecast of 147 USD.
What is Ultragenyx Pharmaceutical Inc's Revenue forecast?
Projected CAGR
28%
The
compound annual growth rate
of Ultragenyx Pharmaceutical Inc's revenue for the next 3 years is
28%.
You don't have any saved screeners yet
